Improvement of Postnatal Neovascularization by Human Adipose Tissue-Derived Stem Cells

Miranville, Alexandra; Heeschen, Christopher; Sengenès, Coralie; Curat, Cyrile Anne; Busse, Rudi; Bouloumié, Anne

doi:10.1161/01.cir.0000135466.16823.d0

Cited by 840 publications

(713 citation statements)

References 26 publications

Supporting

Mentioning

650

Contrasting

Unclassified

Order By: Relevance

“…S1A-S1C). Based on our previous work on human native ASCs [13,25,26] and in accordance with Rodeheffer et al [27], we identified native murine ASCs as the Sca-1 þ /CD45 À /CD31 À cell population. The further immunophenotyping of Sca-1 þ /CD45 À /CD31 À cells showed that murine native ASCs were positive for CD29, CD34, CD90 (Fig.…”

Section: Results Native Immunophenotype In Situ Localization and Momentioning

confidence: 52%

“…ASCs display similar but not identical features with their bone marrow (BM) counterparts, mesenchymal stromal cells (MSCs) [5][6][7][8][9]. Like MSCs, ASCs are endowed with multilineage mesodermal differentiation potentials and exhibit extensive paracrine and immune-modulatory properties [10][11][12][13][14][15]. Most current research is directed at investigating their putative therapeutic properties after their transplantation in damaged and/or degenerating tissues [16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Native Adipose Stromal Cells Egress from Adipose Tissue In Vivo: Evidence During Lymph Node Activation

et al. 2013

View full text Add to dashboard Cite

Adipose tissue (AT) has become accepted as a source of multipotent progenitor cells, the adipose stromal cells (ASCs). In this regard, considerable work has been performed to harvest and characterize this cell population as well as to investigate the mechanisms by which transplanted ASCs mediate tissue regeneration. In contrast the endogenous release of native ASCs by AT has been poorly investigated. In this work, we show that native ASCs egress from murine AT. Indeed, we demonstrated that the release of native ASCs from AT can be evidenced both using an ex vivo perfusion model that we set up and in vivo. Such a mobilization process is controlled by CXCR4 chemokine receptor. In addition, once mobilized from AT, circulating ASCs were found to navigate through lymph fluid and to home into lymph nodes (LN). Therefore, we demonstrated that, during the LN activation, the fat depot encapsulating the activated LN releases native ASCs, which in turn invade the activated LN. Moreover, the ASCs invading the LN were visualized in close physical interaction with podoplanin and ER-TR7 positive structures corresponding to the stromal network composing the LN. This dynamic was impaired with CXCR4 neutralizing antibody. Taken together, these data provide robust evidences that native ASCs can traffic in vivo and that AT might provide stromal cells to activated LNs. STEM CELLS

show abstract

Section: Results Native Immunophenotype In Situ Localization and Momentioning

confidence: 52%

Section: Introductionmentioning

confidence: 99%

Native Adipose Stromal Cells Egress from Adipose Tissue In Vivo: Evidence During Lymph Node Activation

et al. 2013

View full text Add to dashboard Cite

show abstract

“…As expected, the CD34 protein was not detected by cytofluorimetric analysis. CD34 downregulation in MSCs as well as in MTCs could be the result of in vitro culture artifacts, as uncultured SVF and primary culture (within 3 days) of adipose-derived MSCs are CD34 positive (Miranville et al, 2004;PlanatBenard et al, 2004).…”

Section: Phenotype Convergence Between Msc and Mts M Galiè Et Almentioning

confidence: 99%

“…Compared with normal fibroblasts (McAlhany et al, 2003), MTCs have a dramatically enhanced capacity to promote angiogenesis (Orimo et al, 2005), and play a determining role in supporting tumor growth with blood supply (Bhowmick et al, 2004). Likewise, MSCs have exceptional proangiogenic potential, and are thought to have promise for the treatment of ischemic disease (Miranville et al, 2004;Planat-Benard et al, 2004;Cao et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice

et al. 2007

View full text Add to dashboard Cite

Tumor microenvironment in carcinomas recruits mesenchymal cells with an abnormal proangiogenic and invasive phenotype. It is not clear whether mesenchymal tumor cells (MTCs) derive from the activation of mature fibroblasts or from their stem cell precursors. However, stromal cell activation in tumors resembles in several aspects the mesenchymal rearrangement which normally occurs during reparative processes such as wound healing. Mesenchymal stem cells (MSCs) play a crucial role in developmental and reparative processes and have extraordinary proangiogenic potential, on the basis of which they are thought to show great promise for the treatment of ischemic disorders. Here, we show that MTCs have proangiogenic potential and that they share the transcriptional expression of the best-known proangiogenic factors with MSCs. We also found that MTCs and MSCs have the same molecular signature for stemness-related genes, and that when co-implanted with cancer cells in syngeneic animals MSCs determine early tumor appearance, probably by favoring the angiogenic switch. Our data (1) reveal crucial aspects of the proangiogenic phenotype of MTCs, (2) strongly suggest their stem origin and (3) signal the risk of therapeutic use of MSCs in tumorpromoting conditions.

show abstract

“…These cells have been shown to act as a source of angiogenic cytokines, they can undergo endothelial differentiation in vitro, and contribute to neo-vascularization and functional recovery in mouse hind limb ischemia models. 65,66 Embryonic stem cells. An important difference between ES cells and other progenitors is that the former in theory can give rise to all the cell types in the body, while all other cells have limited plasticity.…”

Section: Resident Cardiac Progenitor Cellsmentioning

confidence: 99%

Progress and prospects: Cell based regenerative therapy for cardiovascular disease

2005

View full text Add to dashboard Cite

Experimental and clinical studies are progressing simultaneously to investigate the mechanisms and efficacy of progenitor cell treatment after an acute myocardial infarction and in chronic congestive heart failure. Multipotent progenitor cells appear to be capable of improving cardiac perfusion and/or function; however, the mechanisms still are unclear, and the issue of whether or not trans-differentiation occurs remains unsettled. Both experimentally and clinically, cells originating from different tissues have been shown capable of restoring cardiac function, but more recently multiple groups have identified resident cardiac progenitor cells that seem to participate in regenerating the heart after injury. Clinically, cells originating from blood or bone marrow have been proven to be safe whereas injection of skeletal myoblasts has been associated with the occurrence of ventricular arrhythmias. Myoblasts can transform into rapidly beating myotubes; however, thus far convincing evidence for electro-mechanical coupling between myoblasts and cardiomyocytes is lacking. Moving forward, mechanistic studies will benefit from the use of genetic markers and Cre/lox reporter systems that are less prone to misinterpretation than fluorescent antibodies, and a more convincing answer regarding therapeutic efficacy will come from adequately powered randomized placebo controlled trials. Gene Therapy (2006) 13, 659-671.

show abstract

Improvement of Postnatal Neovascularization by Human Adipose Tissue-Derived Stem Cells

Cited by 840 publications

References 26 publications

Native Adipose Stromal Cells Egress from Adipose Tissue In Vivo: Evidence During Lymph Node Activation

Native Adipose Stromal Cells Egress from Adipose Tissue In Vivo: Evidence During Lymph Node Activation

Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice

Progress and prospects: Cell based regenerative therapy for cardiovascular disease

Contact Info

Product

Resources

About